Haleon (HLN) is trading lower after publishing its Q1 2026 trading statement, showing organic revenue growth of 2.2% for the three months ended March 31, 2026. The company said an unusually weak cold-and-flu season was a key headwind, estimating a roughly 130-basis-point hit to quarterly growth, keeping investors focused on softness in seasonal respiratory demand despite steadier performance in core everyday-health categories. (haleon.com)

By category, Oral Health led with 8.3% organic growth, while Respiratory Health fell 3.4% organically; Pain Relief and Digestive Health were also slightly negative on organic growth. Overall growth was driven by pricing (+2.4%), while volume/mix was down 0.2%, reinforcing concerns that demand trends (not just pricing) are doing more of the work this quarter. (haleon.com)

Haleon reiterated its full-year 2026 outlook for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency, with management expecting growth to accelerate through the remainder of the year. Investors will be listening for more detail on how quickly respiratory demand can normalize, whether North America’s return to growth is sustainable, and any read-through for category elasticity as pricing remains a key contributor. (haleon.com)